EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

How should clinics distinguish 503A, 503B and approved-drug access?

Dose Diligence research deskSection 04 · Page 4 of 17Last updated 17 Nov 2026

Classify the transaction before evaluating the supplier. The following is a diligence framework, not a legal determination.

Proposed arrangementRelevant distinctionEvidence to require
Approved medicine purchased as clinic stockCounterparty authorisation and the clinic’s actual purchasing, dispensing or administration role matter.Exact product/presentation, seller identity, authorisation evidence and applicable traceability responsibilities. FDA has enforced authorised-trading-partner requirements against a medical spa. (fda.gov)
Approved medicine dispensed to a named patientThe clinic may facilitate access without owning the medicine.Identify who receives the prescription, dispenses, charges the patient, ships and handles complaints; document responsibilities in the agreement.
Compounded medicine under 503AThe statute requires an identified patient/prescription framework and other conditions, including restrictions on routine or inordinate copying.Product-specific legal analysis and, when relied upon, the prescriber’s significant-difference determination. (uscode.house.gov)
Compounded medicine under 503BPatient-specific prescriptions are not universally required, but separate bulk-substance and copy restrictions apply.Identify the starting material and establish each relevant statutory condition; do not infer eligibility from office-use capability. (uscode.house.gov)

Can a clinic buy compounded GLP-1 for office use? Office stock and patient-labelled delivery to a clinic are different arrangements. FDA’s prescription guidance explains that section 503A distribution requires patient-specific prescriptions, while qualifying 503B outsourcing facilities can supply non-patient-specific office stock. That general 503B capability does not establish eligibility for bulk-compounded semaglutide or tirzepatide. FDA prescription and office-use guidance. (fda.gov)

Explore the table row by row

A working view of the research

Approved medicine purchased as clinic stock

Relevant distinction
Counterparty authorisation and the clinic’s actual purchasing, dispensing or administration role matter.
Evidence to require
Exact product/presentation, seller identity, authorisation evidence and applicable traceability responsibilities. FDA has enforced authorised-trading-partner requirements against a medical spa. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
  2. uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/?utm_source=openai
  3. uscode.house.gov · Source 3 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/?utm_source=openai
  4. fda.gov · Source 4 ↗https://www.fda.gov/media/97347/download
Section sources →